InvestorsHub Logo
Followers 34
Posts 2888
Boards Moderated 0
Alias Born 04/27/2020

Re: JusDePomme post# 44713

Thursday, 03/02/2023 1:07:06 PM

Thursday, March 02, 2023 1:07:06 PM

Post# of 49319
This statement right here - shows that this company is and will be a game changer in the Cancer field . Wish they were an American company.

This should be trading deep into pennies/silver already…. Quote below from the CEO screams that they’re ready to capitalize.

“Over the last decade, our R&D team has left no stone unturned in preparing for our upcoming milestone in entering the clinical development stage for PRP,” said Mr. Nathanielsz. “When we completed some pivotal milestones, such as receiving future tax credits from the Australian Government, as well as achieving ODE status from the USFDA, provides me with confidence that we are on track to achieve success in our first clinical study, given that clinical data, as well as compelling scientific evidence, is normally required to receive such a designation. As a result, our IP asset pricing reflects a decent valuation, which contrasts significantly to our current market price as a publicly listed entity, which I believe can change when our important R&D milestones are achieved.”